ClinicalTrials.gg
CompletedNCT06288412Updated Jun 8, 2026

A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting

A Phase 1 interventional study of Insulin icodec and Insulin degludec in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Austria. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
21st of 27
30 · median 84
Started
2024
with 1 other
Phase 1
13 of 27
none open now
Registered
24th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 2 that started in 2024, is one of 13 in phase 1, and was the 24th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study will investigate the safety of once weekly insulin icodec subcutaenously (s.c.) during and after exercise and prolonged fasting in patients with type 2 diabetes (T2D). Participants will first receive insulin decludec (Tresiba®, a long-acting insulin taken once daily) for atleast one week. Afterwards participants will receive insulin icodec that will be administered once weekly at the study site (for a minimum of 7 weeks and maximum of 14 weeks). Insulin icodec is a novel long-acting insulin analogue for once-weekly administration for the treatment of type 2 diabetes. The study will last for about 16-30 weeks. Participant must not participate if participant have suspected hypersensitivity reactions to the study products or cardiovascular diseases within the last 180 days. Female participant cannot take part if she is pregnant, breast-feeding or planning to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Male or female.
  • Age 18-75 years (both inclusive) at the time of signing the informed consent.
  • between 18.0 and 38.0 kilogram per meter\^2 (kg/m\^2) (both inclusive).
  • (HbA1c) less than or equal to (\<=) 9 percent (75 millimoles per mole [mmol/mol]) at screening.
  • Treated with basal insulin with or without any of the following anti-diabetic drugs/regimens with stable doses >= 90 days prior to the day of screening:

    • Metformin,
    • Dipeptidyl peptidase 4 (DPP-4) inhibitors,
    • Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  • Oral combination products (for the allowed individual oral antidiabetic drugs), Injectable and oral glucagon-like peptide 1 (GLP-1) Receptor Agonists.
  • Physically active >= 300 metabolic equivalent of task (MET) minutes/week as determined by an International Physical Activity Questionnaire (IPAQ) at screening.
  • Mass-specific oxygen volume (VO2) peak greater than (>) 25 milliliters per kilogram per minute (mL/kg/min) as determined by cardiopulmonary testing (CPX) test at screening.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  • Presence or history of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, , stroke, cardiac decompensation, arrhythmias or clinically significant conduction disorders within 180 days prior to the day of screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Insulin icodec

    Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily in the run-in period and insulin icodec once weekly in the treatment period.

    Drug: Insulin icodec · Drug: Insulin degludec

Interventions

  • Participants will receive insulin icodec subcutaneous (s.c.) once weekly.

  • Participants will receive insulin degludec s.c. once daily.

06

What researchers measure

Primary outcomes

  1. Time below range, glucose less than (<) 3.0 millimoles per liter (mmol/L) (54 milligrams per deciliter [mg/dL]) within 24 hours after start of exercise (TBR3.0mmol/L,exe)

    Measured in percentage of readings.

    Time frame: 0-24 hours after start of exercise at Day 38

Secondary outcomes

  1. Time below range, glucose <3.9 mmol/L (70 mg/dL) within 24 hours after start of exercise (TBR3.9mmol/L,exe)

    Measured in percentage of readings.

    Time frame: 0-24 hours after start of exercise at Day 38

  2. Time in range, glucose 3.9-10.0 mmol/L (70-180 mg/dL) within 24 hours after start of exercise (TIR3.9-10.0mmol/L,exe)

    Measured in percentage of readings.

    Time frame: 0-24 hours after start of exercise at Day 38

  3. Time above range, glucose >10 mmol/L (180 mg/dL) within 24 hours after start of exercise (TAR10.0mmol/L,exe)

    Measured in percentage of readings.

    Time frame: 0-24 hours after start of exercise at Day 38

  4. Number of clinically significant hypoglycaemic episodes during exercise (Hypoexe)

    Measured as number of episodes.

    Time frame: 0-40 minutes after start of exercise at Day 38

  5. Amount of carbohydrate intake during exercise (CHOexe)

    Measured in gram (g).

    Time frame: 0-40 minutes after start of exercise at Day 38

  6. Amount of carbohydrate intake from end of standardised lunch meal until start of exercise (CHOpre-exe)

    Measured in g.

    Time frame: 0-90 minutes before start of exercise at Day 38

  7. Amount of carbohydrate intake after stop of exercise until start of standardised dinner meal (CHOpost-exe)

    Measured in g.

    Time frame: 0-140 minutes after start of exercise at Day 38

  8. Number of hypoglycaemic within 24 hours after start of exercise (Hypo24h,exe)

    Measured as number of episodes.

    Time frame: 0-24 hours after start of exercise at Day 38

  9. Number of hypoglycaemic episodes for 24 hours in reference week (43 to 67 hours after dosing) (Hypo24h,ref)

    Measured as number of episodes.

    Time frame: 43-67 hours after dosing at Day 29

  10. Time below range, glucose <3.0 mmol/L (54 mg/dL) within 18 hours after start of fasting (TBR3.0mmol/L,fast)

    Measured in percentage of readings.

    Time frame: 0-18 hours after start of fasting at Day 44

  11. Time below range, glucose <3.9 mmol/L (70 mg/dL) within 18 hours after start of fasting (TBR3.9mmol/L,fast)

    Measured in percentage of readings.

    Time frame: 0-18 hours after start of fasting at Day 44

  12. Time in range, glucose 3.9-10 mmol/L (70-180 mg/dL) within 18 hours after start of fasting (TIR3.9-10.0mmol/L,fast)

    Measured in percentage of readings.

    Time frame: 0-18 hours after start of fasting at Day 44

  13. Time above range, glucose >10 mmol/L (180 mg/dL) within 18 hours after start of fasting (TAR10.0mmol/L,fast)

    Measured in percentage of readings.

    Time frame: 0-18 hours after start of fasting at Day 44

  14. Number of clinically significant hypoglycaemic episodes during fasting (Hypofast)

    Measured as number of episodes.

    Time frame: 0-18 hours after start of fasting at Day 44

  15. Amount of carbohydrate administered intravenously during fasting (CHOfast)

    Measured in g.

    Time frame: 0-18 hours after start of fasting at Day 44

  16. Number of hypoglycaemic episodes within 18 hours after start of fasting (Hypo18h,fast)

    Measured as number of episodes.

    Time frame: 0-18 hours after start of fasting at Day 44

  17. Number of hypoglycaemic episodes for 18 hours in reference week (26 to 44 hours after dosing) (Hypo18h,ref)

    Measured as number of episodes.

    Time frame: 26-44 hours after dosing at Day 29

07

Study locations

1 site
  • Medical University of Graz
    Graz, 8010, Austria
08

References and documents

Publications

  • Pieber TR, Bajaj HS, Fluhr G, Klein KR, Pagliaro Rocha TM, Sourij H, Svehlikova E, Udupa K, Watt SK, Willerslev-Olsen M, Ribel-Madsen R. Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once-Weekly Basal Insulin Icodec. Diabetes Obes Metab. 2026 Jul 1. doi: 10.1111/dom.71050. Online ahead of print. PubMed 42387301 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Mar 2025, 12 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 12 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 1, 2024
StartActual
Feb 26, 2024
Primary completionActual
Mar 10, 2025
CompletionActual
Apr 14, 2025
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06288412
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Feb 26, 2024
Primary completion
Mar 10, 2025
Completion
Apr 14, 2025
Last update
Jun 8, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion